menu
    • menu

    Company profile for Cullgen

    NEW Drugs in Dev: 3
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    To utilize our revolutionary and proprietary targeted protein degradation technology to create, in a highly efficient manner, new drugs for treatment of diseases that currently lack effective therapies. Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. We are developing our pro...
    To utilize our revolutionary and proprietary targeted protein degradation technology to create, in a highly efficient manner, new drugs for treatment of diseases that currently lack effective therapies. Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. We are developing our proprietary technology platform, uSMITE™, based on recent advances in the science of protein degradation. Typically, drugs are designed to interact with the functional sites of proteins and block their activities.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CullgenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    12671 High Bluff Drive - Suite 130, San Diego, California 92130
    Telephone
    Telephone
    +1 -858-284-0115
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cullgen.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cullgen Ditches Reverse Merger With Pulmatrix To Go With Gyre
    Cullgen Ditches Reverse Merger With Pulmatrix To Go With Gyre

    02 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/cullgen-ditches-reverse-merger-pulmatrix-go-gyre-300m-buyout

    FIERCE BIOTECH
    02 Mar 2026
    Share Share
    Gyre Therapeutics Acquires Cullgen's Targeted Platform & Pipeline
    Gyre Therapeutics Acquires Cullgen's Targeted Platform & Pipeline

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247348/0/en/Gyre-Therapeutics-Enters-into-Agreement-to-Acquire-Cullgen-to-Gain-Targeted-Protein-Degradation-Platform-and-Pipeline.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Cullgen Announces J.P. Morgan Conference Week Participation
    Cullgen Announces J.P. Morgan Conference Week Participation

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214694/0/en/Cullgen-Announces-Conference-Participation-During-J-P-Morgan-Healthcare-Conference-Week.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    Pulmatrix, Cullgen Proceed With Merger, Grant Waivers
    Pulmatrix, Cullgen Proceed With Merger, Grant Waivers

    18 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pulmatrix-and-cullgen-continue-to-pursue-merger-while-granting-each-other-waivers-to-explore-alternatives-302645498.html

    PR NEWSWIRE
    18 Dec 2025
    Share Share
    Cullgen's CG001419 Shows Positive Phase 1 Results
    Cullgen's CG001419 Shows Positive Phase 1 Results

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204662/0/en/Cullgen-Reports-Positive-Results-from-Phase-1-Study-of-its-Novel-Non-Opioid-Product-Candidate-CG001419-for-Pain.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Cullgen Wraps Phase 1 Trial Enrollment for Non-Opioid Pain Drug
    Cullgen Wraps Phase 1 Trial Enrollment for Non-Opioid Pain Drug

    18 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/18/3152268/0/en/Cullgen-Completes-Enrollment-in-Phase-1-Trial-of-its-Novel-Non-Opioid-Pain-Product-Candidate-CG001419.html

    GLOBENEWSWIRE
    18 Sep 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search